|
|
Volumn 114, Issue 9, 2009, Pages 1999-
|
|
Intrathecal MTX for DLBCL: From an inappropriate prophylactic tradition to a medical error?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
METHOTREXATE;
PREDNISONE;
RITUXIMAB;
VINCRISTINE;
ANTINEOPLASTIC AGENT;
CHOP PROTOCOL;
MONOCLONAL ANTIBODY;
BONE MARROW TOXICITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RELAPSE;
CANCER RISK;
CENTRAL NERVOUS SYSTEM;
HUMAN;
INFECTION;
LARGE CELL LYMPHOMA;
LETTER;
MEDICAL ERROR;
MEDICAL INFORMATION;
MULTIPLE CYCLE TREATMENT;
PRIORITY JOURNAL;
STOMATITIS;
CENTRAL NERVOUS SYSTEM DISEASE;
CHEMICALLY INDUCED DISORDER;
IMMUNOLOGY;
IMMUNOTHERAPY;
INTRASPINAL DRUG ADMINISTRATION;
METHODOLOGY;
MULTIMODALITY CANCER THERAPY;
NOTE;
PATHOLOGY;
RISK;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CENTRAL NERVOUS SYSTEM DISEASES;
COMBINED MODALITY THERAPY;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
HUMANS;
IMMUNOTHERAPY;
INJECTIONS, SPINAL;
LYMPHOMA, LARGE B-CELL, DIFFUSE;
MEDICAL ERRORS;
METHOTREXATE;
PREDNISONE;
RESEARCH DESIGN;
RISK;
TREATMENT OUTCOME;
VINCRISTINE;
|
|
EID: 70349251858
PISSN: 00064971
EISSN: 15280020
Source Type: Journal
DOI: 10.1182/blood-2009-05-222570 Document Type: Letter |
|
Times cited : (6)
|
|
References (4)
|
